Zoetis
Zoetis Inc.
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$9.5B
Operating marginCalculated
Could not be retrieved
Net assets to total assetsCalculated
21.5%
Company profile
Tables scroll sideways
Disclosed data
Profitability
Could not be retrieved
Growth (revenue, 4-year average)
★★★☆☆position among all companies
5.0%
Capital efficiency
★★★★★position among all companies
80.2%
Revenue and profit
Performance, financial position and capital allocation
Zoetis
Recent performance trends
Zoetis
Cash flow trends
Consolidated indicators (8 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$7.8 billion | US$8.1 billion | US$8.5 billion | US$9.3 billion | US$9.5 billion |
| Net income | US$2.0 billion | US$2.1 billion | US$2.3 billion | US$2.5 billion | US$2.7 billion |
| Total assets | US$13.9 billion | US$14.9 billion | US$14.3 billion | US$14.2 billion | US$15.5 billion |
| Shareholders' equity | US$4.5 billion | US$4.4 billion | US$5.0 billion | US$4.8 billion | US$3.3 billion |
| Net cash provided by (used in) operating activities | US$2.2 billion | US$1.9 billion | US$2.4 billion | US$3.0 billion | US$2.9 billion |
| Net cash provided by (used in) investing activities | US$-0.5 billion | US$-0.9 billion | US$-0.8 billion | US$-0.3 billion | US$-0.7 billion |
| Net cash provided by (used in) financing activities | US$-1.9 billion | US$-0.9 billion | US$-3.1 billion | US$-2.7 billion | US$-1.9 billion |
| Cash and cash equivalents | US$3.5 billion | US$3.6 billion | US$2.0 billion | US$2.0 billion | US$2.3 billion |
Revenue scale in the same industry
Zoetis
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- … 22 companies
- 26 BiogenFY Dec 2025 US$9.9B
- 27 CelaneseFY Dec 2025 US$9.5B
- 28 ZoetisThis companyFY Dec 2025 US$9.5B
- 29 Eastman ChemicalFY Dec 2025 US$8.8B
- 30 RPM InternationalFY May 2026 US$7.9B
- … 26 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.6 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$2.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-1.9 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.7 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$2.9 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.5 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$3.3 billion | Consolidated | Disclosed |
| Non-controlling interests | US$0 | Consolidated | Disclosed |
| Net assets | US$3.3 billion | Consolidated | Disclosed |
| Net sales | US$9.5 billion | Consolidated | Disclosed |
| Net income | US$2.7 billion | Consolidated | Disclosed |
| Total assets | US$15.5 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$3.2 billion | Consolidated | Disclosed |
| Operating margin | Cannot be calculated | Not applicable | Not calculated (no operating income in this year's 10-K) |
| Net assets to total assets | 21.5% | Consolidated | Calculated |
| Net margin | 28.2% | Consolidated | Calculated |
| Return on equity | 80.2% | Consolidated | Calculated |